| Ronald A Zielinski, MD | |
|
370 East Main Street, Suite 5, Bay Shore, NY 11706 | |
| (631) 666-5864 | |
| (631) 666-1187 |
| Full Name | Ronald A Zielinski |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 41 Years |
| Location | 370 East Main Street, Bay Shore, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912072992 | NPI | - | NPPES |
| 01174294 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | 159730 (New York) | Primary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | 159730 (New York) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| North Shore University Hospital | Manhasset, NY | Hospital |
| Ns/lij Hs Southside Hospital | Bay shore, NY | Hospital |
| Long Island Jewish Medical Center | New hyde park, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North Shore - Lij Medical Pc | 3375701568 | 5099 |
News Archive
Three products for patients with end stage renal disease (ESRD) have been chosen to participate in the FDA's Innovation Pathway, an evolving system designed to help medical devices reach patients in a safe, timely and collaborative manner.
A team of scientists from Canada and Spain recently evaluated the durability of antigen-specific immune responses in COVID-19 recovered individuals. They have also identified potential host factors associated with robust and long-lasting anti-SARS-CoV-2 immunity.
Researchers have generated a new type of human stem cell that can develop into numerous types of specialized cells, including functioning pancreatic beta cells that produce insulin. Called endodermal progenitor (EP) cells, the new cells show two important advantages over embryonic stem cells and induced pluripotent stem cells: they do not form tumors when transplanted into animals, and they can form functional pancreatic beta cells in the laboratory.
Pancreatic cancer is one of the deadliest forms of the disease. The American Cancer Society's most recent estimates for 2014 show that over 46,000 people will be diagnosed with pancreatic cancer and more than 39,000 will die from it. Now, research led by Timothy J. Yen, PhD, Professor at Fox Chase Cancer Center, reveals that one reason this deadly form of cancer can be so challenging to treat is because its cells have found a way to sidestep chemotherapy.
› Verified 7 days ago
| Entity Name | North Shore - Lij Medical Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053688572 PECOS PAC ID: 3375701568 Enrollment ID: O20120220000262 |
News Archive
Three products for patients with end stage renal disease (ESRD) have been chosen to participate in the FDA's Innovation Pathway, an evolving system designed to help medical devices reach patients in a safe, timely and collaborative manner.
A team of scientists from Canada and Spain recently evaluated the durability of antigen-specific immune responses in COVID-19 recovered individuals. They have also identified potential host factors associated with robust and long-lasting anti-SARS-CoV-2 immunity.
Researchers have generated a new type of human stem cell that can develop into numerous types of specialized cells, including functioning pancreatic beta cells that produce insulin. Called endodermal progenitor (EP) cells, the new cells show two important advantages over embryonic stem cells and induced pluripotent stem cells: they do not form tumors when transplanted into animals, and they can form functional pancreatic beta cells in the laboratory.
Pancreatic cancer is one of the deadliest forms of the disease. The American Cancer Society's most recent estimates for 2014 show that over 46,000 people will be diagnosed with pancreatic cancer and more than 39,000 will die from it. Now, research led by Timothy J. Yen, PhD, Professor at Fox Chase Cancer Center, reveals that one reason this deadly form of cancer can be so challenging to treat is because its cells have found a way to sidestep chemotherapy.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ronald A Zielinski, MD 370 East Main Street, Suite 5, Bay Shore, NY 11706 Ph: (631) 666-5864 | Ronald A Zielinski, MD 370 East Main Street, Suite 5, Bay Shore, NY 11706 Ph: (631) 666-5864 |
News Archive
Three products for patients with end stage renal disease (ESRD) have been chosen to participate in the FDA's Innovation Pathway, an evolving system designed to help medical devices reach patients in a safe, timely and collaborative manner.
A team of scientists from Canada and Spain recently evaluated the durability of antigen-specific immune responses in COVID-19 recovered individuals. They have also identified potential host factors associated with robust and long-lasting anti-SARS-CoV-2 immunity.
Researchers have generated a new type of human stem cell that can develop into numerous types of specialized cells, including functioning pancreatic beta cells that produce insulin. Called endodermal progenitor (EP) cells, the new cells show two important advantages over embryonic stem cells and induced pluripotent stem cells: they do not form tumors when transplanted into animals, and they can form functional pancreatic beta cells in the laboratory.
Pancreatic cancer is one of the deadliest forms of the disease. The American Cancer Society's most recent estimates for 2014 show that over 46,000 people will be diagnosed with pancreatic cancer and more than 39,000 will die from it. Now, research led by Timothy J. Yen, PhD, Professor at Fox Chase Cancer Center, reveals that one reason this deadly form of cancer can be so challenging to treat is because its cells have found a way to sidestep chemotherapy.
› Verified 7 days ago
Dr. Nicoleta Ionica, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 180 E Main St, Bay Shore, NY 11706 Phone: 631-780-7800 | |
Paul Howard Broomfield, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 375 E Main St, Ste 21, Bay Shore, NY 11706 Phone: 631-968-8288 Fax: 631-968-8268 | |
Joseph L Saraceno, DO Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 370 East Main Street, Suite 5, Bay Shore, NY 11706 Phone: 631-666-5864 Fax: 631-666-1187 | |
Jason M Golbin, DO Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 370 East Main Street, Bay Shore, NY 11706 Phone: 631-666-5806 Fax: 631-666-1187 | |
Dr. Marie-edouard Nathalie Desvarieux, M.D., M.S. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 3 E Main St, Bay Shore, NY 11706 Phone: 631-666-2290 | |
Dr. Robert Chow, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 40 E Main St, Bay Shore, NY 11706 Phone: 631-376-6075 Fax: 631-539-4092 | |
Dr. Lawrence D. Campbell, M.D. Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 32 E Main St, Bay Shore, NY 11706 Phone: 631-969-9600 Fax: 631-968-7624 |